Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Panorama)
This study is testing a new drug called DT120 for people with Generalized Anxiety Disorder (GAD). DT120 works by affecting a specific receptor in the brain (serotonin 2A receptor). You might be able to join if you are between 18 and 74 years old, have a GAD diagnosis, and a certain score on an anxiety scale (HAM-A total score of 20 or higher). The study will compare DT120 to a placebo (a substance with no medicine in it) to see if DT120 can reduce anxiety symptoms. Researchers will measure changes in your anxiety using the HAM-A scale over 12 weeks. The current recruitment status is unclear.
- Study design
- This is a Phase 3, double-blind, placebo-controlled study, meaning neither you nor your doctor will know if you are receiving DT120 or placebo. It will involve up to 375 participants.
- What's involved
- You would participate in a 12-week treatment period, followed by a 40-week extension phase where you might receive DT120.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your anxiety symptoms will be monitored and evaluated for 12 weeks, with a potential for a 40-week extension phase.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
At a glance
Conditions
Where it's being run
36 sites across 15 statesWho to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12Baseline to Week 12
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.